Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 144-150

  Pace, Craig ^a,b   Markowitz, Martin ^b  

^a GILEAD SCIENCES   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

CCR5; CD4 domain 2; ibalizumab; Keywords bispecific antibodies; PRO 140

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; IBALIZUMAB; PRO 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VIRUS NEUTRALIZATION; HIV INFECTIONS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84928527714     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000146     Document Type: Review

References (28)

1. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat Rev Immunol 2013; 13:693-701.
2. Ho DD and Padte N. Engineering bispecific antibodies for HIV prevention. HIV Research 4 Prevention (R4P); 2014; Cape Town, South Africa. Abstract SY 12.02.
3. Burkly LC, Olson D, Shapiro R, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992; 149:1779-1787.
4. Reimann KA, Lin W, Bixler S, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997; 13:933-943.
5. Moore JP, Sattentau QJ, Klasse PJ, Burkly LC. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4 cells. J Virol 1992; 66:4784-4793.
6. Song R, Franco D, Kao CY, et al. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol 2010; 84:6935-6942.
7. Freeman MM, Seaman MS, Rits-Volloch S, et al. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure 2010; 18:1632-1641.
8. Burastero SE, Frigerio B, Lopalco L, et al. Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4. PLoS One 2011; 6:e22081.
9. Perez-Jimenez R, Alonso-Caballero A, Berkovich R, et al. Probing the effect of force on HIV-1 receptor CD4. ACS Nano 2014; 8:10313-10320.
10. Pace CS, Fordyce MW, Franco D, et al. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr 2013; 62:1-9.
11. Zhang XQ, Sorensen M, Fung M, Schooley RT. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 2006; 50:2231-2233.
12. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189:286-291.
13. Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53:450-457.
14. Norris D, Morales J, Gathe J, et al. TNX-355 in Combination with Optimized Background Regimen (OBR), achieves a statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in Phase 2 study at 48 weeks. 16th International AIDS Conference; 2006; Toronto, Canada. Abstract THLB2018.
15. Khanlou HG, Gathe JC, Schrader S, et al. Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: A Phase 2b study. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011; Chicago, Illinois. Abstract H1-376.
16. Ernst J, Keefer M, Lalezari J, et al. Subcutaneous ibalizumab in at-risk healthy subjects. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014; Washington D.C. Abstract H-995.
17. Toma J, Weinheimer SP, Stawiski E, et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol 2011; 85:3872-3880.
18. Song R, Oren DA, Franco D, et al. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat Biotechnol 2013; 31:1047-1052.
19. Pace CS, Song R, Ochsenbauer C, et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A 2013; 110:13540-13545.
20. Sun M, Pace CS, Yao X, et al. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. J Acquir Immune Defic Syndr 2014; 66:473-483.
21. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
22. Olson WC, Rabut GE, Nagashima KA, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999; 73:4145-4155.
23. Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75:579-588.
24. Pugach P, Ketas TJ, Michael E, Moore JP. Neutralizing antibody and antiretroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 2008; 377:401-407.
25. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345-1352.
26. Jacobson JM, Lalezari JP, Thompson MA, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 2010; 54:4137-4142.
27. Jacobson JM, Thompson MA, Lalezari JP, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 2010; 201:1481-1487.
28. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8:565-571.